Read by QxMD icon Read

Hematology and Oncology

Wendy H Vogel
No abstract text is available yet for this article.
November 2017: Journal of the Advanced Practitioner in Oncology
Zijian Liu, Yuzhu Li, Quanxiang Luo
Our study investigated the relationship between CT signs of colon cancer and the expression of miR-146a, to evaluate their predictive value in early diagnosis and of colon cancer. A total of 216 patients with colon cancer who were admitted to the Department of Hematology and Oncology in Yingcheng Hospital, the Second Hospital of Shandong University in Zhaoyuan City from January 2013 to March 2017 were selected as the study group. At the same time, 150 patients with benign colitis were also included to serve as the control group...
November 2018: Oncology Letters
Olivier Chatelanat, Christian Van Delden, Dan Adler, Pierre-André Guerne, Mathieu Nendaz, Jacques Serratrice
Pneumocystis jirovecii (formely carinii) pneumonia (PcP) affects immunosuppressed patients. Cotrimoxazole prophylaxis has proven to be effective and its indications in HIV patients are well established. In non-HIV patients, the prognosis is poorer and diagnostic tests are of lower sensitivity. Recommendations for prophylaxis in hematology, oncology and solid organ transplantation are based on expert consensus. In rheumatology, the incidence of PcP is mainly related to the administration of corticosteroids. For some inflammatory diseases, a low CD4 cell count, and the administration of anti-TNFα, rituximab or cyclophosphamide may increase the risk...
October 17, 2018: Revue Médicale Suisse
Thomas Vermeulin, Mélodie Lucas, Hélène Marini, Frédéric Di Fiore, Agnès Loeb, Marion Lottin, Hervé Daubert, Christian Gray, Florian Guisier, David Sefrioui, Pierre Michel, Rémy de Mil, Pierre Czernichow, Véronique Merle
INTRODUCTION: During the last decade, most studies on totally implanted venous access-associated adverse events (TIVA-AE) were conducted retrospectively and/or were based on a limited sample size. The aim of our survey was two-fold: to estimate the incidence of TIVA-AE and to identify risk factors in patients with cancer. METHODS: Data from our routine surveillance of TIVA-AE were collected prospectively between October 2009 and January 2011 in two oncology referral centers in Northern France...
October 12, 2018: Bulletin du Cancer
Maryline Bovero, Cristiano Giacomo, Marc Ansari, Marie-José Roulin
PURPOSE: The development of advanced nursing practices (ANP) can meet challenges presented by evolving needs of health care. We aimed at describing the approach taken to implement ANP in a pediatric oncology-hematology unit. METHOD: The Participatory, Evidence-informed, Patient-centered Process for Advanced practice was considered as a conceptual framework for the development, implementation and evaluation of the nursing role. Successive steps were taken for identifying patients and family needs, defining the health care priorities, and establishing a new health care model...
October 2018: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
Harry Menon, Adip Pillai, Jeanine Aussenberg-Rodriguez, John Ambrose, Irini Youssef, Elizabeth A Griffiths, Omar Al Ustwani
Background: Most hospitals still use unfractionated heparin (UFH) as the primary agent for venous thromboembolism (VTE) prophylaxis in the hospital setting due to ease of use and insignificant cost. However, the risk of heparin-induced thrombocytopenia (HIT) has led some groups to favor other options for therapeutic and prophylactic anticoagulation. This is particularly relevant in light of recent data demonstrating a lower rate of HIT in patients receiving enoxaparin compared with UFH...
October 2018: Avicenna Journal of Medicine
Silvio E Perea, Idania Baladrón, Carmen Valenzuela, Yasser Perera
Protein kinase CK2, formerly referred to as casein kinase II, is a serine/threonine kinase often found overexpressed in solid tumors and hematologic malignancies that phosphorylates many substrates integral to the hallmarks of cancer. CK2 has emerged as a viable oncology target having been experimentally validated with different kinase inhibitors, including small molecule ATP-competitors, synthetic peptides, and antisense oligonucleotides. To date only two CK2 inhibitors, CIGB-300 and CX-4945, have entered the clinic in phase 1-2 trials...
January 2018: Seminars in Oncology
Tomonori Hirashima, Yoshitaka Tamura, Yuki Han, Shoji Hashimoto, Ayako Tanaka, Takayuki Shiroyama, Naoko Morishita, Hidekazu Suzuki, Norio Okamoto, Shinobu Akada, Makoto Fujishima, Yoshihisa Kadota, Kazuya Sakata, Akiko Nishitani, Satoru Miyazaki, Takayuki Nagai
BACKGROUND: In our previous study, colorectal cancer (CRC) patients with active Mycobacterium tuberculosis (MTB) tolerated concurrent anti-cancer chemotherapy (anti-CCT) and anti-MTB chemotherapy. In this study, we retrospectively confirmed the efficacy and safety of concurrent chemotherapy in a greater number of patients with different types of malignancies. METHODS: We enrolled 30 patients who were treated concurrently with anti-CCT and anti-MTB regimens between January 2006 and February 2016...
October 12, 2018: BMC Cancer
Christopher Martin Sauer, Jinghui Dong, Leo Anthony Celi, Daniele Ramazzotti
Purpose: Cancer patients are at increased risk of treatment- or disease-related admission to the intensive care unit [1]. Over the past decades, both critical care and cancer care have improved substantially. Due to increased cancer-specific survival [2], we hypothesized that the number of cancer patients admitted to the intensive care unit (ICU) and survival have increased. Materials and Methods: MIMIC-III [3] was used to study trends and outcomes of cancer patients admitted to the ICU between 2002 and 2011...
October 10, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
Takahiro Maeda
In January 2015, President Obama announced his plan to launch the Precision Medicine Initiative. While precision medicine originally refers to a medical model wherein treatments are tailored to individual patients based on their lifestyle, genetic background, and other molecular and physiological test results, genomics-based oncology is most advanced in terms of clinical implementation. Herein, I discuss the benefit of cancer genome sequencing in the field of hematology/oncology and the associated technical and sociomedical challenges...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Joanna Katarzyna Bujak, Rafał Pingwara, Michelle Hase Nelson, Kinga Majchrzak
Cancer immunotherapy is recently considered the most promising treatment for human patients with advanced tumors and could be effectively combined with conventional therapies such as chemotherapy or radiotherapy. Patients with hematological malignancies and melanoma have benefited greatly from immunotherapies such as, adoptive cell transfer therapy, experiencing durable remissions and prolonged survival. In the face of increasing enthusiasm for immunotherapy, particularly for the administration of tumor-specific T lymphocytes, the question arises whether this method could be employed to improve treatment outcomes for canine patients...
October 11, 2018: Acta Veterinaria Scandinavica
Sara Deola, Bella S Guerrouahen, Heba Sidahmed, Anjud Al-Mohannadi, Muhammad Elnaggar, Ramaz Elsadig, Essam M Abdelalim, Goran Petrovski, Massimo Gadina, Adrian Thrasher, Winfried S Wels, Stephen P Hunger, Ena Wang, Francesco M Marincola, Cristina Maccalli, Chiara Cugno
New technologies and therapies designed to facilitate development of personalized treatments are rapidly emerging in the field of biomedicine. Strikingly, the goal of personalized medicine refined the concept of therapy by developing cell-based therapies, the so-called "living drugs". Breakthrough advancements were achieved in this regard in the fields of gene therapy, cell therapy, tissue-engineered products and advanced therapeutic techniques. The Advanced Therapies in Healthcare symposium, organized by the Clinical Research Center Department of Sidra Medicine, in Doha, Qatar (October 2017), brought together world-renowned experts from the fields of oncology, hematology, immunology, inflammation, autoimmune disorders, and stem cells to offer a comprehensive picture of the status of worldwide advanced therapies in both pre-clinical and clinical development, providing insights to the research phase, clinical data and regulatory aspects of these therapies...
October 10, 2018: Journal of Translational Medicine
Zaida Salmón González, Miriam Vieitez Santiago, Maria Martino González, Jose Luis Hernández, Juan Alonso Gutierrez
Tumor lysis syndrome (TLS) is an oncologic emergency. It's characterized by laboratory findings of hyperkaliemia, hyperuricemia, hyperphosphatemia, and hypocalcemia. Disruption is caused by massive tumor cell lysis in which the contents os the lysed tumor cells are released into bloodstream. TLS is a complication that occurs more frequently in hematological tumors or with a large tumor burden, but what is exceptional its appearance spontaneously (STLS). In this article, we report a case of STLS in a patient with gastric adenocarcinoma...
October 9, 2018: QJM: Monthly Journal of the Association of Physicians
Zeina Al-Mansour, Muthalagu Ramanathan, Jan Cerny
The incidence of most hematological malignancies increases with age. Despite the higher incidence of hematological malignancies in the elderly, the geriatric population is poorly represented in the early oncology clinical trials that established the current standards of care. Hematopoietic cell transplant (HCT), either upfront or at relapse, provides a potentially life-prolonging, often curative option for many patients with hematological malignancies and is considered the standard of care, at least for younger patients...
October 9, 2018: Drugs & Aging
Philip McCarthy
Philip McCarthy speaks to Roshaine Wijayatunga, Senior Editor: Oncology Philip McCarthy completed his MD at Tufts University School of Medicine, Boston, MA, USA and his Internal Medicine Residency at Yale, New Haven Hospital, New Haven, CT, USA. His Fellowship was completed at Brigham and Women's Hospital and the Dana Farber Cancer Insitute, Harvard University, Boston, MA, USA. His research interests are devoted to developing novel intensive and reduced intensity allogeneic (allo) and autologous (auto) hematopoietic stem cell transplant (HSCT) approaches for the treatment of hematologic disorders, leading to improved patient outcomes and decreased toxicity...
December 2017: International Journal of Hematologic Oncology
Joshua Richter, Sundar Jagannath
During the past decade, the survival outcomes of patients with multiple myeloma (MM) have dramatically improved, not only owing to the advent of a number of novel therapies, but also to the deepening insight regarding how to best use these options. Triplet-based induction regimens can yield overall response rates of ≤ 100%. In the relapsed and refractory setting, we have a multitude of doublet and triplet options available with high and durable response rates. The addition of monoclonal antibodies has provided a new class of agents to augment our standard approach with novel therapies...
September 20, 2018: Clinical Lymphoma, Myeloma & Leukemia
Jeremy S Stultz, Rose Kohinke, Amy L Pakyz
BACKGROUND: Identification of factors associated with antifungal utilization in neonatal, pediatric, and adult patient groups is needed to guide antifungal stewardship initiatives in academic medical centers. METHODS: For this hospital-level analysis, we analyzed antifungal use in hospitals across the United States of America, excluding centers only providing care for hematology/oncology patients. Analysis of variance was used to compare antifungal use between patient groups...
October 3, 2018: BMC Infectious Diseases
Sara L Revolinski, L Silvia Munoz-Price
Clostridium difficile is a significant pathogen in healthcare today, impacting both hospitalized and community-based patients. Immunocompromised patients experience a high incidence of C. difficile infection, ranging from 6% to 33% in the hematology-oncology population, up to 23% among lung transplant recipients, and a rate of 7.1-8.3 cases per 1000 patient years in patients with human immunodeficiency virus. Recurrence of C. difficile infections among immunocompromised patients is also high, with rates up to 40% in both the hematology-oncology population and solid organ transplant recipients...
October 3, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Jacek Przemyslaw Grabowski, Rolf Richter, Hannah Rittmeister, Radoslav Chekerov, Hannah Woopen, Jalid Sehouli
BACKGROUND/AIM: Chemotherapy-associated toxicity is one of the limiting factors regarding treatment efficacy, patient outcome and quality of life in this collective. Underweight or obese patients represent a major group in which the therapy seems to be more challenging. The aim of this analysis was to evaluate the impact of BMI on the toxicity in patients undergoing chemotherapy. PATIENTS AND METHODS: The data of three prospective phase II/III studies ('Tower', 'Topotecan phase III' and 'Hector') of the North-Eastern German Society of Gynecological Oncology including 1,213 patients with recurrent ovarian cancer were retrospectively analyzed...
October 2018: Anticancer Research
Pablo A I Slullitel, Fernando Díaz Dilernia, Joaquín Stagnaro, Mariano Revah, Liliana Rojas, Https/Orcid Org/ Ma Lourdes Posadas-Martinez, Martín A Buttaro, Gastón A Slullitel
BACKGROUND: In high-risk patients, common prophylaxis may be insufficient to prevent thromboembolic events after orthopaedic procedures. In this scenario, a retrievable vena cava filter (VCF) could be considered as an alternative, although it's use remains controversial. Therefore, we asked: (1) what is the overall mechanical complication rate associated with the use of retrievable VCFs in orthopaedic surgery?, (2) what is the association with thromboembolic disease (TED) recurrence, post-thrombotic syndrome and/or major bleeding according to different surgical characteristics?, (3) What is the overall mortality rate attributed to VCF use? METHODS: We retrospectively analyzed a cohort of 68 patients who underwent orthopaedic surgery with a previous diagnosis of TED, in whom a retrievable VCF was placed...
June 11, 2018: Revista de la Facultad de Ciencias Médicas
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"